Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Oklahoma City, Oklahoma 73104


Purpose:

A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.


Study summary:

Six different dosages of tamoxifen will be given for 14 days with safety and viral loads being measured.


Criteria:

Inclusion Criteria: 1. HCV RNA positive. 2. failed standard therapy Exclusion Criteria: 1. Cirrhosis on biopsy 2. Severe medical or psychiatric conditions that would make the evaluation difficult 3. Tamoxifen is a pregnancy category D drug so pregnant women must be excluded. 4. Patients with coumadin cannot be used from a drug interaction. 5. Active use of alcohol or illegal substances -


NCT ID:

NCT00749138


Primary Contact:

Principal Investigator
Ted Bader
OUHSC


Backup Contact:

N/A


Location Contact:

Oklahoma City, Oklahoma 73104
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.